跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 142 条关于
“225Ac-OncoACP3”
全部
142
临床试验
49
药物
69
机构
0
资讯
24
去年
Bristol Myers Squibb Subsidiary RayzeBio Acquires OncoACP3 Radiopharmaceutical for Prostate Cancer in $1.35 Billion Deal
4年前
Phase 1/2 Trial Investigates 225Ac-J591 and 177Lu-PSMA-I&T Combination in Metastatic Castration-Resistant Prostate Cancer
去年
Ariceum Therapeutics Presents Promising Data on 225Ac-Satoreotide at EANM 2024
4年前
Preliminary Data on 225Ac-J591 Shows Promise in Treating mCRPC
2年前
FDA Grants Fast Track Designation to 225Ac-FL-020 for Metastatic Castration-Resistant Prostate Cancer
去年
Bristol Myers Squibb Acquires Novel Prostate Cancer Radiopharmaceutical for $1.35 Billion
11个月前
Ariceum Therapeutics Advances 225Ac-SSO110 for Extensive Stage Small Cell Lung Cancer with Novel Radioligand Therapy Approach
去年
Ariceum's 225Ac-Satoreotide Receives FDA Orphan Drug Designation and IND Clearance for SCLC and Merkel Cell Carcinoma
9天前
FDA Clears IND for Full-Life's Actinium-225 c-MET Radioconjugate [225Ac]Ac-FL-261 in Non-Squamous NSCLC
11个月前
Full-Life Technologies Secures $77 Million Series C to Advance Radiopharmaceutical Pipeline and Manufacturing
第 1 页,共 3 页
上一页
下一页